Serge A. Jabbour MD

Diabetes, Lipid Metabolism

Director, Division of Endocrinology, Professor of Medicine, Thomas Jefferson University

211 S 9th St, Ste 600Philadelphia, PA 19107
Phone+1 215-955-1925
Fax+1 215-928-3160

Dr. Jabbour is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jabbour's full profile Already have an account?

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1994 - 1997
St Joseph's University Medical SchoolClass of 1993
La Sagesse CollegeBachelors, Experimental Sciences, 1983 - 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 1997 - 2026
FL State Medical License 2021 - 2023
NJ State Medical License 1999 - 2003
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Complete), Allscripts, 2012-2017

Clinical Trials

Dapagliflozin DPPIV Inhibitor add-on Study
COMPLETED
PHASE3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
COMPLETED
PHASE3
Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight
COMPLETED
NA

Publications & Presentations

PubMed

Role of the trigeminal system in pancreatic innervation: new concept and challenge - a narrative review.
Fady M Bou Malhab, Serge A Jabbour, Ralph Defronzo, Rita Nemr
Endocrine Research. 2026-05-01
Heterozygous Hereditary Vitamin D-Dependent Rickets Type 2A (VDDR2A) in a Patient Presenting With Pseudoarthrosis.
Risa Goldberg, Gunjan Umarji, Serge Jabbour
Case Reports in Endocrinology. 2025-01-01
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.
Donald C Simonson, Marcia A Testa, Ella Ekholm, Maxwell Su, Tina Vilsbøll
The Journal of Clinical Endocrinology and Metabolism. 2024-11-18

Journal Articles

Safety and Efficacy of Exenatide Once Weekly plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Contro...
Serge Jabbour, MD, Diabetes Care
An Open Label Randomized Phase II Study of Pasireotide With or Without Everolimus in Castrate-Resistant Chemotherapy-Naïve Prostate Cancer Patients
Lin J, Deng A, Hoffman-Censits J, Gibney G, Hyslop T, Miller B, Kilpatrick D, Jabbour S, Kelly WK, Cancer Treatment Communications, 1/1/2015
Incidence and Severity of Pancreatogenic Diabetes after Pancreatic Resection
Burkhart RA, Gerber SM, Tholey RM, Lamb KM, Somasundaram A, McIntyre CA, Fradkin EC, Ashok AP, Felte RF, Mehta JM, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, and Winter JM, Journal of Gastrointestinal Surgery, 1/1/2015

Books/Book Chapters

International Textbook of Diabetes Mellitus
Chapter: Glycated Hemoglobin and Serum Proteins as Tools for Monitoring
Page 853 - 874Gerber S, Ahmed I, Stickle D, Jabbour SAEditors: DeFronzo R, Ferranini E, Zimmet P, and Alberti G.Wiley-Blackwell, Oxford, EnglandEdition 4th,2015
Case Reports in Endocrinology
Chapter: Ovarian Leydig Cell Hyperplasia: An Unusual Case of Virilization in a Post-Menopausal Woman
Mehta JM, Miller JL, Cannon AJ, Mardekian SK, Kenyon AJ, Jabbour SAHindawi Publishing Corporation2014
Tarascon Adult Endocrinology Pocketbook
Chapter: Hypoglycemia
Page 321 - 324Donohue K, Jabbour SAEditors: Laufgraben M and Gopalakrishnan G.2013

Abstracts/Posters

Robust Dose-dependent Glucose Lowering and Body Weight (BW) Reductions with the Novel Oral Formulation of Semaglutide in Patients with early Type 2 Diabetes (T2D)
Jabbour S, Pieber T, Rosenstock J, Hartoft-Nielsen ML, Højbjerg Hansen OK, Davies M, The Endocrine Society, Boston, MA, 1/1/2016
Patient characteristics and real world effectiveness of dapagliflozin; an observational analysis of US electronic health records
Jabbour S, Bell K, Eudicone J, Shatskov A, Katz A, WCIR, 13th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Los Angeles, CA, 1/1/2015
Incidence of Radioiodine-induced Gastritis and the Dosage of I-131 Ablation for Differentiated Thyroid Cancer: Results of a Multi-year Analysis
Intenzo C, Jabbour SA, Miller J, Kim S, Furlong K, Ahmed I, SNMMI (Society of Nuclear Medicine and Molecular Aging) Annual Meeting, Baltimore, MD, 1/1/2015

Lectures

Guideline-Based Approach to Manage T2DM: Place of SGLT2-Inhibitors
Lucknow, India - 1/31/2015
Improving the Metabolic State in T2DM Patients & Associated Risks
Lucknow, India - 1/29/2015
Glucocorticoids and HPA Axis Suppression
Philadelphia, PA - 1/24/2015

Other

Modern Oral Agents in Clinical Practice: Where do SGLT2 Inhibitors Fit
Jabbour SA, Medscape
http://www.medscape.org/viewarticle/833998
1/1/2014
Clinical Decision Support: Dermatology
Boban I, Jabbour SA
1/1/2012
Syndrome X
Jabbour SA, Miller JL, World Book, Inc.
www.worldbookonline.com
1/21/2004

Press Mentions

COVID-19 and Diabetes, What You Need to KnowOctober 29th, 2021
Combo Drug Treatment for Type 2 Diabetes Remains Effective After Two YearsNovember 2nd, 2020
Clinical Endocrinology Update Goes Bicoastal for a Second YearJuly 30th, 2019